Marvel Announces Identification of a Novel Formulation of Its MB-204 Asset

About this update from Marvel Biosciences Corp

[{"type":"text","content":"Marvel Announces Identification of a Novel Formulation of Its MB-204 AssetCalgary, Alberta--(Newsfile Corp. - July 21, 2022) - Marvel Biosciences Inc. (TSXV: MRVL) (the \"Company\" or \"Marvel\") is pleased to announce that its rapid formulation screening program with Catalent, Inc., has identified a novel formulation of its lead asset MB-204.The formulation involves producing a solid amorphous dispersion of MB-204 using a simple, FDA approved excipient that has improved drug exposures by at least a factor of 20-fold. Improving oral bioavailability results in reduced amounts of drug needed to achieve a target dose which could in turn reduce costs and/or side effects. \"We are very pleased with the results and the efforts of Catalent, Inc.,\" said Dr. Mark Williams, Chief Science Officer of Marvel Biosciences. \"This represents yet another important milestone for Marvel. The Company is moving quickly to produce enough formulated material to begin our 4-week GLP toxicology, and in parallel, we are set to begin the cGMP manufacturing of MB-204. We remain committed to advancing MB-204 to the clinic in the next two quarters.\"Contact InformationInvestor Relations: Virtus Advisory GroupTel: 416-644-5081Email: [email protected] Biosciences Corp.Roderick (Rod) Matheson, Chief Executive Officer orDr. Mark Williams, President and Chief Science OfficerTel: 403 770 2469Email: [email protected] the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.All information contained in this news release with respect to the Company and its subsidiary, (collectively, the \"Parties\") were supplied by Marvel, respectively, for inclusion herein and each parties' directors and officers have relied on each other for any information concerning such Party.This news release may contain forward-looking statements and other statements that are not historical facts. Forward-looking statements are often identified by terms such as \"will\", \"may\", \"should\", \"anticipate\", \"expects\" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of the Company are fo...

More updates from Marvel Biosciences Corp